1
|
Blanc-Durand F, Pautier P, Michels J, Leary A. Targeting the immune microenvironment in ovarian cancer therapy-mission impossible? ESMO Open 2024; 9:102936. [PMID: 38492450 PMCID: PMC10955311 DOI: 10.1016/j.esmoop.2024.102936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Revised: 01/22/2024] [Accepted: 02/09/2024] [Indexed: 03/18/2024] Open
Affiliation(s)
- F Blanc-Durand
- Medical Oncology Department, Gyneco-oncology unit, Institut Gustave Roussy, Villejuif; INSERM UMR981, Institut Gustave Roussy, Villejuif, France
| | - P Pautier
- Medical Oncology Department, Gyneco-oncology unit, Institut Gustave Roussy, Villejuif
| | - J Michels
- Medical Oncology Department, Gyneco-oncology unit, Institut Gustave Roussy, Villejuif
| | - A Leary
- Medical Oncology Department, Gyneco-oncology unit, Institut Gustave Roussy, Villejuif; INSERM UMR981, Institut Gustave Roussy, Villejuif, France.
| |
Collapse
|
2
|
Grau Béjar J, Yaniz Galende E, Genestie C, Scoazec JY, Edmond E, Le Formal A, Blanc-Durand F, Michels J, Kfoury M, Morice P, Pautier P, Colomba-Blameble E, Leary A. 182MO Immune co-regulator (co-reg) expression in mismatch repair-deficient (MMRd) endometrial cancer (EC) patients (pts): Anti-PD-(L)1-responders (R) versus (vs) non-responders (NR). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
3
|
Velghe F, De Wilde F, Snellinx S, Farahbakhsh S, Belderbos E, Peral C, Wiedemann A, Hiessl S, Michels J, Pierrard MA, Dietrich T. Volatile fatty acid platform - a cornerstone for the circular bioeconomy. FEMS Microbiol Lett 2021; 368:6283740. [PMID: 34036338 DOI: 10.1093/femsle/fnab056] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Accepted: 05/21/2021] [Indexed: 11/13/2022] Open
Abstract
Annually, the EU produces more than 100 million tonnes of urban biowaste, which is largely under-valorized and in some cases even still landfilled without any energy or material recovery. If Europe wants to be ready for the future, it will need to make better use of this large biomass potential within a circular economy approach. The research project funded by the European Commission under the Horizon 2020 programme entitled 'VOLATILE-Biowaste derived volatile fatty acid platform for biopolymers, bioactive compounds and chemical building blocks' aimed to produce volatile fatty acids (VFAs) from biowaste for reprocessing into products, materials or substances to close the material loop. During the project, the partners were able to obtain average volatile fatty acid yields of 627 g COD/kg organic matter (OM) for food waste, 448 g COD/kg OM for separately collected vegetable, garden and fruit waste (VGF) and 384 g COD/kg OM for the organic fraction of municipal solid waste (OF-MSW) at concentrations ranging from 12 to 48 g/L, 6 to 40 g/L and 13 to 26 g/L, respectively. A membrane filtration cascade consisting of micro-, ultra- and nano-filtration followed by reverse osmosis was identified as a feasible way to purify and concentrate the VFA effluent, making them a suitable carbon source for further fermentation processes. Besides technical optimization, socio-economic and legal aspects associated with this platform technology were also studied and show that although this technology is still in development, it is providing an answer to changing societal and market expectations both regarding organic waste treatment and bio-based production strategies. Based on the current technological, economic and market evolutions, it is expected that the VFAP will play an important role in organic waste treatment in the coming years.
Collapse
Affiliation(s)
- F Velghe
- OWS nv, Dok-Noord 5, 9000 Gent, Belgium
| | | | - S Snellinx
- Social Sciences Unit, Institute for Agricultural and Fisheries Research, Burg. Van Gansberghelaan 115 Bus 2, 9820 Merelbeke, Belgium
| | - S Farahbakhsh
- Social Sciences Unit, Institute for Agricultural and Fisheries Research, Burg. Van Gansberghelaan 115 Bus 2, 9820 Merelbeke, Belgium
| | - E Belderbos
- Social Sciences Unit, Institute for Agricultural and Fisheries Research, Burg. Van Gansberghelaan 115 Bus 2, 9820 Merelbeke, Belgium
| | - C Peral
- TECNALIA, Basque Research and Technology Alliance (BRTA), Parque Tecnológico de Álava, Leonardo Da Vinci 1, 01510 Miñano, Álava, Spain
| | - A Wiedemann
- Wiedemann GmbH, Rieblinger Str. 25, 86479 Aichen, Germany
| | - S Hiessl
- DECHEMA e.V., Theodor-Heuss-Allee 25, 60486 Frankfurt am Main, Germany
| | - J Michels
- DECHEMA e.V., Theodor-Heuss-Allee 25, 60486 Frankfurt am Main, Germany
| | - M-A Pierrard
- IDELUX Environnement, drève de l'arc-en-ciel 98, 6700 arlon, Belgium
| | - T Dietrich
- TECNALIA, Basque Research and Technology Alliance (BRTA), Parque Tecnológico de Álava, Leonardo Da Vinci 1, 01510 Miñano, Álava, Spain
| |
Collapse
|
4
|
Colomba-Blameble E, Pautier P, Michels J, Pommeret F, Kfoury M, Maulard A, Gouy S, Morice P, Genestie C, Leary A. 848P Features and clinical outcomes for younger women with epithelial ovarian cancer (EOC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
5
|
Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, Marabelle A, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C, Delaloge S, McGranahan N, André F, Zitvogel L. T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants. Ann Oncol 2019; 30:934-944. [PMID: 30924846 PMCID: PMC7614969 DOI: 10.1093/annonc/mdz112] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Tumor-infiltrating lymphocytes (TILs) represent a prognostic factor for survival in primary breast cancer (BC). Nonetheless, neoepitope load and TILs cytolytic activity are modest in BC, compromising the efficacy of immune-activating antibodies, which do not yet compete against immunogenic chemotherapy. PATIENTS AND METHODS We analyzed by functional flow cytometry the immune dynamics of primary and metastatic axillary nodes [metastatic lymph nodes (mLN)] in early BC (EBC) after exposure to T-cell bispecific antibodies (TCB) bridging CD3ε and human epidermal growth factor receptor 2 (HER2) or Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5), before and after chemotherapy. Human leukocyte antigen (HLA) class I loss was assessed by whole exome sequencing and immunohistochemistry. One hundred primary BC, 64 surrounding 'healthy tissue' and 24 mLN-related parameters were analyzed. RESULTS HLA loss of heterozygosity was observed in EBC, at a clonal and subclonal level and was associated with regulatory T cells and T-cell immunoglobulin and mucin-domain-3 expression restraining the immuno-stimulatory effects of neoadjuvant chemotherapy. TCB bridging CD3ε and HER2 or CEACAM5 could bypass major histocompatibility complex (MHC) class I loss, partially rescuing T-cell functions in mLN. CONCLUSION TCB should be developed in BC to circumvent low MHC/peptide complexes.
Collapse
Affiliation(s)
- M Messaoudene
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France
| | - T P Mourikis
- Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK
| | - J Michels
- Gustave Roussy Cancer Campus (GRCC), Villejuif; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif
| | - Y Fu
- Gustave Roussy Cancer Campus (GRCC), Villejuif
| | - M Bonvalet
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France
| | - M Lacroix-Trikki
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
| | - B Routy
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Universitéde Montréal Hospital Research Centre (CRCHUM), Onco-Hematology Department, Montreal University Hospital Center (CHUM), Montréal, Québec, Canada
| | - A Fluckiger
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
| | - S Rusakiewicz
- Center of Experimental Therapeutics (CET), Department of Oncology, Lausanne University Hospital, CHUV, Lausanne, Switzerland
| | - M P Roberti
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
| | - S Cotteret
- Gustave Roussy Cancer Campus (GRCC), Villejuif
| | - C Flament
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
| | - V Poirier-Colame
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
| | - N Jacquelot
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif
| | - F Ghiringhelli
- Georges-François Leclerc center, Medical Oncology, Dijon
| | - A Caignard
- INSERM U1160, University Institute for Haematology, Saint Louis hospital, Paris
| | | | - G Kroemer
- Gustave Roussy Cancer Campus (GRCC), Villejuif; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus, Cordeliers Research Center, INSERM, U1138, Université Paris Descartes, Sorbonne Paris Cité; Université Pierre et Marie Curie; Pôle de Biologie, Européen Georges Pompidou Hospital, AP-HP, Paris
| | - A Marabelle
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Gustave Roussy Cancer Campus (GRCC), Drug Development Department (DITEP), Villejuif
| | - M Arnedos
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif
| | - C Vicier
- Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France
| | - S Dogan
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France
| | - F Jaulin
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France
| | - S-J Sammut
- Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge
| | - W Cope
- Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge; Cancer Research UK Cancer Centre and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - C Caldas
- Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge
| | - S Delaloge
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif
| | - N McGranahan
- Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK
| | - F André
- Gustave Roussy Cancer Campus (GRCC), Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif; Gustave Roussy Cancer Campus (GRCC), INSERM U981, Villejuif, France
| | - L Zitvogel
- Gustave Roussy Cancer Campus (GRCC), Villejuif; National Institute of Health and Medical Research (INSERM) U1015, Villejuif, France; University Paris-Sud, University Paris-Saclay, Gustave Roussy Cancer Campus (GRCC), Villejuif; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
| |
Collapse
|
6
|
Edith B, Leary A, Pautier P, Santana E, Lacroix L, Cabaret O, Guillaud-Bataille M, Michels J, Auguste A, Genestie C, Rouleau E. Combined tumor-based BRCA/TP53 mutation testing in ovarian cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Mesnage SJL, Auguste A, Genestie C, Dunant A, Pain E, Drusch F, Gouy S, Morice P, Bentivegna E, Lhomme C, Pautier P, Michels J, Le Formal A, Cheaib B, Adam J, Leary AF. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann Oncol 2017; 28:651-657. [PMID: 27864219 DOI: 10.1093/annonc/mdw625] [Citation(s) in RCA: 127] [Impact Index Per Article: 18.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Lymphocytic infiltration at diagnosis is prognostic in EOC, however, the impact of NACT on tumour infiltrating lymphocytes (TILs) or PD-L1 expression remains poorly described. Patients and methods Patients with EOC and sequential samples (pre-NACT, post-NACT or relapse) were retrospectively identified. TILs were evaluated on whole sections; stromal TILs (sTILs) scored as percentage of stromal area with high sTILs defined as ≥50%; intra-epithelial TILs (ieTILs) scored semi-quantitatively (0-3) with high ieTILs ≥2. A smaller number were available for PD-L1 evaluation, cut-off for positivity was ≥5% staining. Results sTILs were detected in all tumours at diagnosis (range 2-90%, median 20%), with 22% (25/113) showing high sTILs. Among evaluable paired pre/post-NACT samples (N = 83), an overall increase in median sTILs from 20% to 30% was seen following NACT (P = 0.0005); individually the impact of NACT varied with sTILs increasing in 51% (42/83), decreasing in 25%, and stable in 24%. Post-NACT sTILs were predictive of platinum-free interval (PFI), patients with PFI ≥6 months had significantly higher post-NACT sTILs (sTILs 28% versus 18% for PFI <6 months, P = 0.026); pre-NACT sTILS were not predictive. At diagnosis, 23% showed high ieTILs, and following NACT 33% showed increasing ieTILs. Proportion of tumours with PD-L1-positive immune cells was 30% (15/50) pre-NACT and 53% (27/51) post-NACT (P = 0.026). Among paired tumours, 63% of PD-L1-negative tumours became positive after NACT, furthermore cisplatin induced PD-L1 expression in PD-L1-negative EOC cell lines. On multivariate analysis, high sTILs both pre- and post-NACT were independent prognostic factors for progression-free survival (PFS) (HR 0.49, P = 0.02 and HR 0.60, P = 0.05, respectively). No prognostic impact of ieTILs or PD-L1 expression was detected. Conclusions In EOC, sTILs levels are prognostic at diagnosis and remain prognostic after NACT. TILs and PD-L1 expression increase following NACT. Evaluation of immune parameters in the post-NACT tumour may help select patients for immunotherapy trials.
Collapse
Affiliation(s)
- S J L Mesnage
- INSERM U981 Gynaecological Tumours, Gustave Roussy Cancer Center, Villejuif
| | - A Auguste
- INSERM U981 Gynaecological Tumours, Gustave Roussy Cancer Center, Villejuif.,Faculty of Sciences, University Paris-Sud, Orsay
| | - C Genestie
- INSERM U981 Gynaecological Tumours, Gustave Roussy Cancer Center, Villejuif.,Departments of Biopathology, Gustave Roussy, Villejuif, France
| | - A Dunant
- Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France
| | - E Pain
- INSERM U981 Gynaecological Tumours, Gustave Roussy Cancer Center, Villejuif
| | - F Drusch
- Translational Research and Histocytopathology Laboratory, Gustave Roussy, 114 rue E Vaillant, 94805, Villejuif, France
| | - S Gouy
- Gustave Roussy, Université Paris-Saclay, Department of Gynecologic Surgery, F-94805, Villejuif, France
| | - P Morice
- Gustave Roussy, Université Paris-Saclay, Department of Gynecologic Surgery, F-94805, Villejuif, France
| | - E Bentivegna
- Gustave Roussy, Université Paris-Saclay, Department of Gynecologic Surgery, F-94805, Villejuif, France
| | - C Lhomme
- Oncology, Gustave Roussy Cancer Center, Villejuif, France
| | - P Pautier
- Oncology, Gustave Roussy Cancer Center, Villejuif, France
| | - J Michels
- Oncology, Gustave Roussy Cancer Center, Villejuif, France
| | - A Le Formal
- INSERM U981 Gynaecological Tumours, Gustave Roussy Cancer Center, Villejuif.,Faculty of Sciences, University Paris-Sud, Orsay
| | - B Cheaib
- Oncology, Gustave Roussy Cancer Center, Villejuif, France
| | - J Adam
- INSERM U981 Gynaecological Tumours, Gustave Roussy Cancer Center, Villejuif.,Departments of Biopathology, Gustave Roussy, Villejuif, France
| | - A F Leary
- INSERM U981 Gynaecological Tumours, Gustave Roussy Cancer Center, Villejuif.,Faculty of Sciences, University Paris-Sud, Orsay.,Oncology, Gustave Roussy Cancer Center, Villejuif, France
| |
Collapse
|
8
|
Khairallah A, Auguste A, Leary A, Genestie C, Pautier P, Michels J, Morice P, Bentivegna E, Maulard A, Drusch F, Mesnage S, Gouy S. An increased ratio of cytotoxic to suppressive T cells after neoadjuvant chemotherapy (NACT) is prognostic in advanced ovarian cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Leary A, Genestie C, Boursin Y, Adam J, Leformal-Ensarguex A, Gouy S, Morice P, Bentivegna E, Pautier P, Michels J, Job B, Deloger M, Mesnage S, Auguste A. Genomic instability is associated with increased immune infiltration and PDL1 expression in epithelial ovarian cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Gawlitza J, Michels J, Borggrefe M, Schönberg S, Akin I, Saur J, Trinkmann F, Henzler T. Time to exhale: Evaluierung des diagnostischen Mehrwerts von Thorax CT Untersuchungen in Expiration bei Patienten mit COPD – Ergebnisse der CType Studie. ROFO-FORTSCHR RONTG 2017. [DOI: 10.1055/s-0037-1600442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- J Gawlitza
- Universitätsmedizin Mannheim, Institut für klinische Radiologie, Mannheim
| | - J Michels
- Universitätsmedizin Mannheim, 1. medizinische Klinik, Mannheim
| | - M Borggrefe
- Universitätsmedizin Mannheim, 1. medizinische Klinik, Mannheim
| | - S Schönberg
- Universitätsmedizin Mannheim, Institut für klinische Radiologie, Mannheim
| | - I Akin
- Universitätsmedizin Mannheim, 1. medizinische Klinik, Mannheim
| | - J Saur
- Universitätsmedizin Mannheim, 1. medizinische Klinik, Mannheim
| | - F Trinkmann
- Universitätsmedizin Mannheim, 1. medizinische Klinik, Mannheim
| | - T Henzler
- Universitätsmedizin Mannheim, Institut für klinische Radiologie, Mannheim
| |
Collapse
|
11
|
Michels J, Saur D, Roth K, Saur J, Trinkmann F. Lung Clearance Index bei Patienten mit obstruktiven Ventilationsstörungen. Pneumologie 2016. [DOI: 10.1055/s-0036-1572015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
12
|
Trinkmann F, Berger M, Papavassiliu T, Michels J, Schoenberg S, Borggrefe M, Doesch C, Saur J. Electrical Velocimetry zur nicht-invasiven Bestimmung des Herzzeitvolumens: Einfluss der Elektrodenposition auf die Messgenauigkeit. Pneumologie 2016. [DOI: 10.1055/s-0036-1572024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Michels J, Adam J, Goubar A, Obrist F, Damotte D, Robin A, Alifano M, Vitale I, Olaussen KA, Girard P, Cremer I, Castedo M, Soria JC, Kroemer G. Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. Ann Oncol 2015; 26:2470-7. [PMID: 26387143 DOI: 10.1093/annonc/mdv393] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2015] [Accepted: 09/13/2015] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Cisplatin-resistant non-small cell lung cancer (NSCLC) cells are often characterized by alterations in vitamin B-related metabolic processes, including the overexpression and hyperactivation of poly(ADP-ribose) polymerase 1 (PARP1) and the downregulation of pyridoxal kinase (PDXK), correlating with elevated apoptosis resistance. Low PDXK expression is an established negative prognostic factor in NSCLC. PATIENTS AND METHODS We determined by immunohistochemistry the expression of PARP1 and the level of its product, poly(ADP-ribose) (PAR), in two independent cohorts of patients with resected NSCLC. RESULTS Intratumoral high levels (above median) of PAR (but not PARP1 protein levels) had a negative prognostic impact in both the training (92 stage I subjects) and validation (133 stage I and II subjects) cohorts, as determined by univariate and multivariate analyses. The simultaneous assessment of PAR and PDXK protein levels improved risk stratification. CONCLUSION NSCLC patients with high intratumoral PARP1 activity (i.e. elevated PAR levels above median) and low PDXK expression (below median) had a dismal prognosis, while patients with low PARP1 activity and high PDXK expression had a favorable outcome. Altogether, these results underscore the clinical potential and possible therapeutic relevance of these biomarkers.
Collapse
Affiliation(s)
- J Michels
- INSERM UMR1138 Group 11, Cordeliers Research Centre, Paris Department of Medical Oncology, Gustave Roussy Comprehensive Cancer Center, Villejuif Paris-Sud University, Villejuif
| | - J Adam
- Paris-Sud University, Villejuif Department of Pathology, Gustave Roussy Comprehensive Cancer Center, Villejuif INSERM U981, Villejuif
| | | | - F Obrist
- INSERM UMR1138 Group 11, Cordeliers Research Centre, Paris Pierre and Marie Curie University, Paris
| | - D Damotte
- INSERM UMR1138 Group 11, Cordeliers Research Centre, Paris Pierre and Marie Curie University, Paris Department of Pathology and Thoracic Surgery, Cochin Hospital, AP-HP, Paris Paris Descartes University, Paris, France
| | | | - M Alifano
- Department of Pathology and Thoracic Surgery, Cochin Hospital, AP-HP, Paris Paris Descartes University, Paris, France
| | - I Vitale
- Regina Elena National Cancer Institute, Rome Department of Biology, University of Rome 'TorVergata', Rome, Italy
| | - K A Olaussen
- Paris-Sud University, Villejuif INSERM U981, Villejuif
| | - P Girard
- Thoracic Department, Mutualiste Montsouris Institute, Paris
| | - I Cremer
- INSERM UMR1138 Group 11, Cordeliers Research Centre, Paris Pierre and Marie Curie University, Paris Paris Descartes University, Paris, France
| | - M Castedo
- INSERM UMR1138 Group 11, Cordeliers Research Centre, Paris Pierre and Marie Curie University, Paris
| | - J-C Soria
- Paris-Sud University, Villejuif INSERM U981, Villejuif Department of Drug Development, Gustave Roussy Comprehensive Cancer Center, Villejuif
| | - G Kroemer
- INSERM UMR1138 Group 11, Cordeliers Research Centre, Paris Pierre and Marie Curie University, Paris Paris Descartes University, Paris, France Metabolomics Platform, Gustave Roussy Comprehensive Cancer Center, Villejuif Department of Biology, Georges Pompidou European Hospital, AP-HP, Paris, France
| |
Collapse
|
14
|
Trinkmann F, Klein J, Michels J, Borggrefe M, Saur J. Hämodynamische Effekte von inhalativem Fenoterol und Ipratropium bei Patienten mit obstruktiven Lungenerkrankungen. Pneumologie 2015. [DOI: 10.1055/s-0035-1544769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
15
|
Michels J. Der BMEL-Forschungsverbund „Lignocellulose Bioraffinerie”︁. CHEM-ING-TECH 2014. [DOI: 10.1002/cite.201450428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
16
|
Vaccheli E, Michels J, Hadoux J, Lotz JP. American association for cancer research — AACR congress 2014. ONCOLOGIE 2014. [DOI: 10.1007/s10269-014-2414-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
17
|
Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014; 5:e1257. [PMID: 24874729 PMCID: PMC4047912 DOI: 10.1038/cddis.2013.428] [Citation(s) in RCA: 538] [Impact Index Per Article: 53.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2013] [Revised: 09/23/2013] [Accepted: 09/26/2013] [Indexed: 12/16/2022]
Abstract
The platinum derivative cis-diamminedichloroplatinum(II), best known as cisplatin, is currently employed for the clinical management of patients affected by testicular, ovarian, head and neck, colorectal, bladder and lung cancers. For a long time, the antineoplastic effects of cisplatin have been fully ascribed to its ability to generate unrepairable DNA lesions, hence inducing either a permanent proliferative arrest known as cellular senescence or the mitochondrial pathway of apoptosis. Accumulating evidence now suggests that the cytostatic and cytotoxic activity of cisplatin involves both a nuclear and a cytoplasmic component. Despite the unresolved issues regarding its mechanism of action, the administration of cisplatin is generally associated with high rates of clinical responses. However, in the vast majority of cases, malignant cells exposed to cisplatin activate a multipronged adaptive response that renders them less susceptible to the antiproliferative and cytotoxic effects of the drug, and eventually resume proliferation. Thus, a large fraction of cisplatin-treated patients is destined to experience therapeutic failure and tumor recurrence. Throughout the last four decades great efforts have been devoted to the characterization of the molecular mechanisms whereby neoplastic cells progressively lose their sensitivity to cisplatin. The advent of high-content and high-throughput screening technologies has accelerated the discovery of cell-intrinsic and cell-extrinsic pathways that may be targeted to prevent or reverse cisplatin resistance in cancer patients. Still, the multifactorial and redundant nature of this phenomenon poses a significant barrier against the identification of effective chemosensitization strategies. Here, we discuss recent systems biology studies aimed at deconvoluting the complex circuitries that underpin cisplatin resistance, and how their findings might drive the development of rational approaches to tackle this clinically relevant problem.
Collapse
Affiliation(s)
- L Galluzzi
- 1] Gustave Roussy, Villejuif, France [2] Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France [3] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France
| | - I Vitale
- 1] Regina Elena National Cancer Institute, Rome, Italy [2] National Institute of Health, Rome, Italy
| | - J Michels
- 1] Gustave Roussy, Villejuif, France [2] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France [3] INSERM, U848, Villejuif, France
| | - C Brenner
- 1] INSERM, UMRS 769; LabEx LERMIT, Châtenay Malabry, France [2] Faculté de Pharmacie, Université de Paris Sud/Paris XI, Châtenay Malabry, France
| | - G Szabadkai
- 1] Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, UK [2] Department of Biomedical Sciences, Università Degli Studi di Padova, Padova, Italy
| | - A Harel-Bellan
- 1] Laboratoire Epigenetique et Cancer, Université de Paris Sud/Paris XI, Gif-Sur-Yvette, France [2] CNRS, FRE3377, Gif-Sur-Yvette, France [3] Commissariat à l'Energie Atomique (CEA), Saclay, France
| | - M Castedo
- 1] Gustave Roussy, Villejuif, France [2] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France [3] INSERM, U848, Villejuif, France
| | - G Kroemer
- 1] Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France [2] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France [3] INSERM, U848, Villejuif, France [4] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France [5] Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France
| |
Collapse
|
18
|
Galluzzi L, Vacchelli E, Michels J, Garcia P, Kepp O, Senovilla L, Vitale I, Kroemer G. Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. Oncogene 2013. [PMID: 23334322 DOI: 10.1038/onc.2012.623[epubaheadofprint]] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
Pyridoxal-5'-phosphate (PLP), the bioactive form of vitamin B6, reportedly functions as a prosthetic group for >4% of classified enzymatic activities of the cell. It is therefore not surprising that alterations of vitamin B6 metabolism have been associated with multiple human diseases. As a striking example, mutations in the gene coding for antiquitin, an evolutionary old aldehyde dehydrogenase, result in pyridoxine-dependent seizures, owing to the accumulation of a metabolic intermediate that inactivates PLP. In addition, PLP is required for the catabolism of homocysteine by transsulfuration. Hence, reduced circulating levels of B6 vitamers (including PLP as well as its major precursor pyridoxine) are frequently paralleled by hyperhomocysteinemia, a condition that has been associated with an increased risk for multiple cardiovascular diseases. During the past 30 years, an intense wave of clinical investigation has attempted to dissect the putative links between vitamin B6 and cancer. Thus, high circulating levels of vitamin B6, as such or as they reflected reduced amounts of circulating homocysteine, have been associated with improved disease outcome in patients bearing a wide range of hematological and solid neoplasms. More recently, the proficiency of vitamin B6 metabolism has been shown to modulate the adaptive response of tumor cells to a plethora of physical and chemical stress conditions. Moreover, elevated levels of pyridoxal kinase (PDXK), the enzyme that converts pyridoxine and other vitamin B6 precursors into PLP, have been shown to constitute a good, therapy-independent prognostic marker in patients affected by non-small cell lung carcinoma (NSCLC). Here, we will discuss the clinical relevance of vitamin B6 metabolism as a prognostic factor in cancer patients.
Collapse
Affiliation(s)
- L Galluzzi
- 1] Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France [2] Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Michels J, Hadoux J, Deutsch E. Métabolisme et cancer. ONCOLOGIE 2013. [DOI: 10.1007/s10269-013-2327-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
20
|
Galluzzi L, Vacchelli E, Michels J, Garcia P, Kepp O, Senovilla L, Vitale I, Kroemer G. Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. Oncogene 2013; 32:4995-5004. [PMID: 23334322 DOI: 10.1038/onc.2012.623] [Citation(s) in RCA: 92] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2012] [Revised: 11/21/2012] [Accepted: 11/26/2012] [Indexed: 12/17/2022]
Abstract
Pyridoxal-5'-phosphate (PLP), the bioactive form of vitamin B6, reportedly functions as a prosthetic group for >4% of classified enzymatic activities of the cell. It is therefore not surprising that alterations of vitamin B6 metabolism have been associated with multiple human diseases. As a striking example, mutations in the gene coding for antiquitin, an evolutionary old aldehyde dehydrogenase, result in pyridoxine-dependent seizures, owing to the accumulation of a metabolic intermediate that inactivates PLP. In addition, PLP is required for the catabolism of homocysteine by transsulfuration. Hence, reduced circulating levels of B6 vitamers (including PLP as well as its major precursor pyridoxine) are frequently paralleled by hyperhomocysteinemia, a condition that has been associated with an increased risk for multiple cardiovascular diseases. During the past 30 years, an intense wave of clinical investigation has attempted to dissect the putative links between vitamin B6 and cancer. Thus, high circulating levels of vitamin B6, as such or as they reflected reduced amounts of circulating homocysteine, have been associated with improved disease outcome in patients bearing a wide range of hematological and solid neoplasms. More recently, the proficiency of vitamin B6 metabolism has been shown to modulate the adaptive response of tumor cells to a plethora of physical and chemical stress conditions. Moreover, elevated levels of pyridoxal kinase (PDXK), the enzyme that converts pyridoxine and other vitamin B6 precursors into PLP, have been shown to constitute a good, therapy-independent prognostic marker in patients affected by non-small cell lung carcinoma (NSCLC). Here, we will discuss the clinical relevance of vitamin B6 metabolism as a prognostic factor in cancer patients.
Collapse
Affiliation(s)
- L Galluzzi
- 1] Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France [2] Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Michels J, Cochereau D, Thibault C. Brèves de l’AERIO. ONCOLOGIE 2012. [DOI: 10.1007/s10269-012-2220-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
22
|
Abstract
Resilin is a rubber-like protein found in the exoskeleton of arthropods. It often contributes large proportions to the material of certain structures in movement systems. Accordingly, the knowledge of the presence and distribution of resilin is essential for the understanding of the functional morphology of these systems. Because of its specific autofluorescence, resilin can be effectively visualized using fluorescence microscopy. However, the respective excitation maximum is in the UV range, which is not covered by the lasers available in most of the modern commercial confocal laser scanning microscopes. The goal of this study was to test the potential of confocal laser scanning microscopy (CLSM) in combination with a 405 nm laser to visualize and analyse the presence and distribution of resilin in arthropod exoskeletons. The results clearly show that all resilin-dominated structures, which were visualized successfully using wide-field fluorescence microscopy (WFM) and a 'classical' UV excitation, could also be visualized efficiently with the proposed CLSM method. Furthermore, with the application of additional laser lines CLSM turned out to be very appropriate for studying differences in the material composition within arthropod exoskeletons in great detail. As CLSM has several advantages over WFM with respect to detailed morphological imaging, the application of the proposed CLSM method may reveal new information about the micromorphology and material composition of resilin-dominated exoskeleton structures leading to new insights into the functional morphology and biomechanics of arthropods.
Collapse
Affiliation(s)
- J Michels
- Department of Functional Morphology and Biomechanics, Institute of Zoology, Christian-Albrechts-Universität zu Kiel, Germany.
| | | |
Collapse
|
23
|
Abstract
Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis. Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure. An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described. Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting molecular circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance). As in some clinical settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clinical implications.
Collapse
Affiliation(s)
- L Galluzzi
- INSERM, U848 Apoptosis, Cancer and Immunity, Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Michels J, Rey A, Duvillard P, Morice P, Caron O, Leteuff G, Savoye A, Gouy S, Lhomme C, Pautier P. 8049 POSTER Epithelial Ovarian Carcinoma in Very Young Women: Age-specific Characteristics. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72137-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
25
|
Dawel G, Kastner M, Michels J, Poppitz W, Gunther W, Fritsche W. Structure of a laccase-mediated product of coupling of 2,4-diamino-6-nitrotoluene to guaiacol, a model for coupling of 2,4,6-trinitrotoluene metabolites to a humic organic soil matrix. Appl Environ Microbiol 2010; 63:2560-5. [PMID: 16535637 PMCID: PMC1389192 DOI: 10.1128/aem.63.7.2560-2565.1997] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
This work presents laccase-mediated model reactions for coupling of reduced 2,4,6-trinitrotoluene (TNT) metabolites to an organic soil matrix. The structure of an isolated coupling product of 2,4-diamino-6-nitrotoluene (2,4-DANT) to guaiacol as humic constituent was determined. Among several structures, the compound was identified conclusively to be the trinuclear coupling product 5-(2-amino-3-methyl-4-nitroanilino)-3,3(prm1)-dimethoxy-4,4(prm1)-diphenoqu inone. The compound has a weight of 409 g mol(sup-1) and may serve as a model reaction for the biogenic formation of bound residues in soil from TNT by coupling aminotoluenes (reduced TNT metabolites) to humic constituents. A linear correlation of the substrate consumption to the enzyme activity was detected. Based on this observation, the described reaction of 2,4-DANT coupling to guaiacol may be used for determination of laccase activity since the reaction was not inhibited by other compounds of culture supernatants. We propose a two-step mechanism for the coupling reaction because 2,4-DANT was not transformed by laccases in the absence of guaiacol and guaiacol oxidation was independent of the presence of 2,4-DANT. The first reaction step is a laccase-mediated dimerization of two guaiacol monomers with subsequent oxidation to a diphenoquinone. The second step is the nucleophilic addition of 2,4-DANT to the ortho position of the carbonyl group of the diphenoquinone structure.
Collapse
|
26
|
Italiano A, Mathoulin-Pelissier S, Terrier P, Le Cesne A, Bonvalot S, Collin F, Michels J, Blay J, Coindre J, Bin Bui N. Trends in survival for metastatic soft-tissue sarcoma: A French Sarcoma Group (GSF) database analysis. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Affiliation(s)
- J Michels
- Department of Functional Morphology and Biomechanics, Institute of Zoology, Christian-Albrechts-Universität zu Kiel, Germany.
| | | |
Collapse
|
28
|
Michels J, Kerzel S, Gronow A, Maier RF, Haas H, Zemlin M. Das „Interleukin–4-induzierende Prinzip“ von Schistosoma mansoni-Eiern (IPSE) ist ein B-Zell-Superantigen. Klin Padiatr 2010. [DOI: 10.1055/s-0030-1251060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
29
|
Michels J, Ellard SL, Le L, Kollmannsberger C, Murray N, Tomlinson Guns ES, Carr R, Chi KN. A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Ann Oncol 2009; 21:305-311. [PMID: 19633045 DOI: 10.1093/annonc/mdp311] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND This study investigated the safety, pharmacokinetics (PK) and clinical antitumor activity of ABT-751, a novel sulfonamide antimitotic and vascular disrupting agent, in combination with docetaxel (Taxotere) in patients with castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS Patients received docetaxel (60-75 mg/m(2)) i.v. on day 1 and ABT-751 (100-200 mg) orally daily for 14 days, repeated every 3 weeks for up to 10 times on four escalating dose levels (DLs). RESULTS Thirty-two patients received a median of 8.5 treatment cycles (range 1-10). One of six patients on DL 3 (D 60 mg/m(2) + A 200 mg) and 4 (D 75 mg/m(2) + A 200 mg) experienced dose-limiting toxicity, and both DLs were expanded. Overall, severe adverse events occurred more commonly on DL 4 than 3 (47% versus 18% of patients). PK data for docetaxel and ABT-751 were similar to reported literature. Best post-treatment prostate-specific antigen decline of > or =50% occurred in 60% and objective responses occurred in 45% of patients. Median overall survival was 24 months (95% confidence interval 8.3-37.7 months). CONCLUSIONS The combination of ABT-751 and docetaxel is safe and active in CRPC. Based on the cumulative safety analysis, the recommended phase II dose of ABT-751 is 200 mg daily with docetaxel 60 mg/m(2) for this patient population.
Collapse
Affiliation(s)
- J Michels
- Department of Medical Oncology, Vancouver Centre, British Columbia Cancer Agency, Vancouver; Department of Medical Oncology, Vancouver Island Centre, British Columbia Cancer Agency, Victoria
| | - S L Ellard
- Department of Medical Oncology, Southern Interior Centre, British Columbia Cancer Agency, Kelowna
| | - L Le
- Department of Medical Oncology, Fraser Valley Centre, British Columbia Cancer Agency, Surrey
| | - C Kollmannsberger
- Department of Medical Oncology, Vancouver Centre, British Columbia Cancer Agency, Vancouver
| | - N Murray
- Department of Medical Oncology, Vancouver Centre, British Columbia Cancer Agency, Vancouver
| | - E S Tomlinson Guns
- The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
| | - R Carr
- Abbott Laboratories, Abbott Park, IL, USA
| | - K N Chi
- Department of Medical Oncology, Vancouver Centre, British Columbia Cancer Agency, Vancouver.
| |
Collapse
|
30
|
Italiano A, Delva F, Brouste V, Terrier P, Trassard M, Michels J, Collin F, Coindre J, Blay J, Bui B. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: A multivariate analysis of the French Sarcoma Group database. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10504] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10504 Background: The SMAC meta-analysis failed to demonstrate that adjuvant chemotherapy (AC) significantly improves overall survival (OS) in adult patients with localised resectable soft-tissue sarcoma (STS). We report here the analysis of the impact of AC in the population of STS patients included in the prospective database of the French Sarcoma Group. Methods: Between 1980 and 1999, 2,029 pts with STS were admitted to one of the 20 tertiary cancer centers of the GSF for the management of a first tumoral event and were included prospectively in a comprehensive database. 152 pts were excluded from the study because of metastatic disease at diagnosis. All the cases were reviewed by the pathology subcommittee of the GSF. Tumor grade was assessed according to the FNCLCC system based on tumor differentiation, mitotic count, and necrosis. Results: 283 pts (14.5%) had grade 1, 736 (39.5%) grade 2 and 858 (46%) grade 3 tumors. 1,102 pts (59%) had extremity tumors. The commonest pathological subtypes were MFH 22.5%, liposarcoma 18%, leiomyosarcoma 13%, and synovial sarcoma 10%. 1,122 pts (60%) received adjuvant radiotherapy. AC was delivered in 16 grade 1 pts (6%), 167 grade 2 pts (23%) and 323 grade 3 pts (38%). The majority of patients who received AC had tumors with a deep topography (91%) and/or > 5 cm (75%) and/or located in the limbs (61%). The median follow-up was 9 years. The 5 year-OS was 90% for grade 1 pts, 63% for grade 2 pts and 46% for grade 3 pts. On multivariate analysis ( table 1 ), AC was strongly associated with improved metastasis-free survival (MFS) (5 year MFS: 53% vs 47%, HR 0.7 [0.5–0.9], p=0.003) and overall survival (OS) (5 year OS: 56% vs 44%, HR 0.7 [0.5–0.8], p=0.004) in grade 3 pts. This association was not observed in grade 2 pts (5 year MFS: 73% vs 72%, HR 0.9 [0.6–1.4], p=0.9; 5 year OS: 73% vs 65%, HR 0.7 [0.5–1.1]). Conclusions: This large cohort-based analysis with long-term follow-up indicates that FNCLCC grade 3 pts are likely to benefit from AC. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- A. Italiano
- French Sarcoma Group (GSF-GETO); Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre René Huguenin, Saint-Cloud, France; Centre François Baclesse, Caen, France; Centre George-François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France
| | - F. Delva
- French Sarcoma Group (GSF-GETO); Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre René Huguenin, Saint-Cloud, France; Centre François Baclesse, Caen, France; Centre George-François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France
| | - V. Brouste
- French Sarcoma Group (GSF-GETO); Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre René Huguenin, Saint-Cloud, France; Centre François Baclesse, Caen, France; Centre George-François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France
| | - P. Terrier
- French Sarcoma Group (GSF-GETO); Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre René Huguenin, Saint-Cloud, France; Centre François Baclesse, Caen, France; Centre George-François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France
| | - M. Trassard
- French Sarcoma Group (GSF-GETO); Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre René Huguenin, Saint-Cloud, France; Centre François Baclesse, Caen, France; Centre George-François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France
| | - J. Michels
- French Sarcoma Group (GSF-GETO); Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre René Huguenin, Saint-Cloud, France; Centre François Baclesse, Caen, France; Centre George-François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France
| | - F. Collin
- French Sarcoma Group (GSF-GETO); Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre René Huguenin, Saint-Cloud, France; Centre François Baclesse, Caen, France; Centre George-François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France
| | - J. Coindre
- French Sarcoma Group (GSF-GETO); Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre René Huguenin, Saint-Cloud, France; Centre François Baclesse, Caen, France; Centre George-François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France
| | - J. Blay
- French Sarcoma Group (GSF-GETO); Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre René Huguenin, Saint-Cloud, France; Centre François Baclesse, Caen, France; Centre George-François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France
| | - B. Bui
- French Sarcoma Group (GSF-GETO); Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Centre René Huguenin, Saint-Cloud, France; Centre François Baclesse, Caen, France; Centre George-François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France
| |
Collapse
|
31
|
Hirte HW, McGuire W, Edwards R, Husain A, Hoskins P, Michels J, Matulonis U, Sexton C, Michelson G. A phase II trial of voreloxin in women with platinum-resistant ovarian cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5559] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5559 Background: Voreloxin is a naphthyridine analog that intercalates DNA and inhibits topoisomerase II, inducing apoptosis. Clinical activity has been observed in ovarian cancer and AML. Results are reported from a fully enrolled phase II study of 3 dose levels of single agent voreloxin in patients (pts) with 1° or 2° platinum-resistant or refractory ovarian cancer. Methods: Pts may have received ≤ 3 prior platinum regimens plus one additional non-platinum regimen. PS of 0–1 was required. Voreloxin regimens: Cohort A 48 mg/m2q3weeks (wk) (N = 65), Cohort B 60 mg/m2q4wk (N = 35), and Cohort C 75 mg/m2q4wk (N = 35) by short IV infusion. BRCA status is reported by pt consent. Results: Cohort A: 2CRs, 5PRs; ORR 11%; median PFS 82 days (52–98 days 95%CI); Cohort B: 1CR, 3PRs; ORR 11%, median PFS too early to evaluate (TETE); Cohort C - TETE. Cohort A: Febrile neutropenia (FN) incidence was low (8%). Other common G3 or G4 AEs reported (≥ 5%) were fatigue (14%) and nausea (5%). Dose delays or reductions (40%) occurred typically at Cycle 1, largely due to neutropenia. Cohort B: Dose was increased to 60 mg/m2 and dosing interval was lengthened to 4 wk, maintaining dose intensity (DI) and allowing adequate time for marrow recovery. ANC dosing criterion was changed from ANC ≥ 1,500 to ≥ 1,000. There was a marked decrease in dose delays and reductions (14%) with only 3% incidence of FN. Common G3 or 4 AEs reported (≥ 5%) were fatigue (11%) and nausea (5%). The safety profile supported further dose escalation to 75 mg/m2q4wk (Cohort C- DI increased by 25%). Data are TETE. Conclusions: Preliminary data suggest Cohorts A and B have similar safety and efficacy profiles as anticipated based on comparable DI. Fewer dose reductions and delays occurred in Cohort B, due to revised dosing criteria and increased cycle length to 4 wk. Accrual to Cohort C is complete. Efficacy and safety data for all cohorts will be reported. [Table: see text]
Collapse
Affiliation(s)
- H. W. Hirte
- Juravinski Cancer Centre, Hamilton, ON, Canada; Weinberg Cancer Center, Baltimore, MD; University of Pittsburgh, Pittsburgh, PA; Stanford University, Palo Alto, CA; BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Sunesis Pharmaceuticals Inc, South San Francisco, CA
| | - W. McGuire
- Juravinski Cancer Centre, Hamilton, ON, Canada; Weinberg Cancer Center, Baltimore, MD; University of Pittsburgh, Pittsburgh, PA; Stanford University, Palo Alto, CA; BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Sunesis Pharmaceuticals Inc, South San Francisco, CA
| | - R. Edwards
- Juravinski Cancer Centre, Hamilton, ON, Canada; Weinberg Cancer Center, Baltimore, MD; University of Pittsburgh, Pittsburgh, PA; Stanford University, Palo Alto, CA; BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Sunesis Pharmaceuticals Inc, South San Francisco, CA
| | - A. Husain
- Juravinski Cancer Centre, Hamilton, ON, Canada; Weinberg Cancer Center, Baltimore, MD; University of Pittsburgh, Pittsburgh, PA; Stanford University, Palo Alto, CA; BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Sunesis Pharmaceuticals Inc, South San Francisco, CA
| | - P. Hoskins
- Juravinski Cancer Centre, Hamilton, ON, Canada; Weinberg Cancer Center, Baltimore, MD; University of Pittsburgh, Pittsburgh, PA; Stanford University, Palo Alto, CA; BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Sunesis Pharmaceuticals Inc, South San Francisco, CA
| | - J. Michels
- Juravinski Cancer Centre, Hamilton, ON, Canada; Weinberg Cancer Center, Baltimore, MD; University of Pittsburgh, Pittsburgh, PA; Stanford University, Palo Alto, CA; BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Sunesis Pharmaceuticals Inc, South San Francisco, CA
| | - U. Matulonis
- Juravinski Cancer Centre, Hamilton, ON, Canada; Weinberg Cancer Center, Baltimore, MD; University of Pittsburgh, Pittsburgh, PA; Stanford University, Palo Alto, CA; BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Sunesis Pharmaceuticals Inc, South San Francisco, CA
| | - C. Sexton
- Juravinski Cancer Centre, Hamilton, ON, Canada; Weinberg Cancer Center, Baltimore, MD; University of Pittsburgh, Pittsburgh, PA; Stanford University, Palo Alto, CA; BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Sunesis Pharmaceuticals Inc, South San Francisco, CA
| | - G. Michelson
- Juravinski Cancer Centre, Hamilton, ON, Canada; Weinberg Cancer Center, Baltimore, MD; University of Pittsburgh, Pittsburgh, PA; Stanford University, Palo Alto, CA; BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Sunesis Pharmaceuticals Inc, South San Francisco, CA
| |
Collapse
|
32
|
McGuire WP, Hirte HW, Matulonis UA, Penson RT, Husain A, Hoskins PJ, Michels J, Michelson G, Chiang A, Aghajanian CA. A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Abstract
The utility of cuticular autofluorescence for the visualization of copepod morphology by means of confocal laser scanning microscopy (CLSM) was examined. Resulting maximum intensity projections give very accurate information on morphology and show even diminutive structures such as small setae in detail. Furthermore, CLSM enables recognition of internal structures and differences in material composition. Optical sections in all layers and along all axes of the specimens can be obtained by CLSM. The facile and rapid preparation method bears no risk of artefacts or damage occurring to the preparations and the visualized specimens can be used for later analyses allowing for the investigation of irreplaceable type specimens or parts of them. These features make CLSM a very effective tool for both taxonomical and ecological studies in small crustaceans; however, the maximum thickness of the specimens is limited to a few hundred micrometers. Three-dimensional models based on CLSM image stacks allow observation of the preparations from all angles and can permit, improve and speed up studies on functional morphology. The visualization method described has a strong potential to become a future standard technique in aquatic biology due to its advantages over conventional light microscopy and scanning electron microscopy.
Collapse
Affiliation(s)
- J Michels
- Alfred-Wegener-Institut für Polar- und Meeresforschung, PO Box 120161, 27515 Bremerhaven, Germany.
| |
Collapse
|
34
|
Habens F, Lapham AS, Dallman CL, Pickering BM, Michels J, Marcusson EG, Johnson PWM, Packham G. Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytes. Oncogene 2006; 26:1910-9. [PMID: 16983335 DOI: 10.1038/sj.onc.1209979] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Bcl-X(L) is a Bcl-2-related survival protein that is essential for normal development. Bcl-X(L) expression is rapidly induced by a wide range of survival signals and many cancer cells constitutively express high levels. The Bcl-X gene has a complex organization with multiple promoters giving rise to RNAs with alternate 5' non-coding exons. Here we have investigated the mechanisms that control basal and induced expression of Bcl-X(L) in B-lymphoma cells. Antisense experiments demonstrated that Bcl-X(L) was essential for survival of Akata6 B-lymphoma cells. The levels of RNAs containing the IB Bcl-X non-coding exon, derived from the distal 1B promoter, correlated with basal expression of Bcl-X(L) in primary malignant B cells and this promoter was highly active in B-cell lines. The activity of this promoter was largely dependent on a single Ets binding site and Ets family proteins were bound at this promoter in intact cells. CD40 ligand (CD40L)-induced cell survival was associated with increased Bcl-X(L) expression and accumulation of exon IA-containing RNAs, derived from the proximal 1A promoter. Nuclear factor-kappaB (NF-kappaB) inhibition prevented induction of Bcl-X(L) protein and exon IA-containing RNAs by CD40L. Therefore, the distal Bcl-X 1B promoter plays a critical role in driving constitutive expression-mediated via Ets family proteins in malignant B cells, whereas NF-kappaB plays a central role in the induction of Bcl-X(L) in response to CD40 signalling via the proximal 1A promoter.
Collapse
Affiliation(s)
- F Habens
- Cancer Research UK Clinical Centre, Cancer Sciences Division, University of Southampton School of Medicine, Southampton General Hospital, Southampton, UK
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Michels J, Geldart T, Darby A, Craddock L, Iveson A, Richardson L, Iveson T. The Combination of Raltitrexed (Tomudex) and Mitomycin-C in the Treatment of Advanced Colorectal Cancer — A Phase II Study. Clin Oncol (R Coll Radiol) 2006; 18:431-5. [PMID: 16909964 DOI: 10.1016/j.clon.2006.01.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
AIMS To investigate the combination of raltitrexed and mitomycin-C as first-line chemotherapy treatment in patients with advanced colorectal cancer. MATERIALS AND METHODS A phase II study. RESULTS In total, 22 patients were treated with a combination of raltitrexed 3 mg/m2 every 3 weeks and mitomycin-C 7 mg/m2 every 6 weeks for up to 24 weeks. The study was closed early for safety reasons as there were three unexpected treatment-related deaths. The overall response rate was 20%, and a further 40% achieved stable disease. The median time to progression was 3.9 months and the median overall survival time was 11.6 months. CONCLUSION Owing to the potential for increased toxicity, the combination of raltitrexed and mitomycin-C cannot be recommended as first-line treatment in patients with advanced colorectal cancer.
Collapse
Affiliation(s)
- J Michels
- Oncology Unit, Southampton General Hospital, UK
| | | | | | | | | | | | | |
Collapse
|
36
|
Guillou L, Coindre J, Gallagher G, Terrier P, Gebhard S, de Saint Aubain Somerhausen N, Michels J, Jundt G, Vince DR, Collin F, Trassard M, Le Doussal V, Benhattar J. Detection of the synovial sarcoma translocation t(X;18) (SYT;SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists. A molecular analysis of 221 mesenchymal tumors fixed in different fixatives. Hum Pathol 2001; 32:105-12. [PMID: 11172303 DOI: 10.1053/hupa.2001.21130] [Citation(s) in RCA: 121] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Synovial sarcoma (SS) is a relatively rare sarcoma, which may be confused with several other mesenchymal and nonmesenchymal lesions. It bears the t(X;18) (SYT;SSX) translocation, which seems to be specific for this tumor type and can be detected in paraffin-embedded tissue, using reverse transcriptase-polymerase chain reaction (RT-PCR). However, the specificity and sensitivity of this detection method have rarely been examined in a large series. Using RT-PCR, we examined 250 mesenchymal and nonmesenchymal, benign and malignant, paraffin-embedded lesions for the SS t(X;18) (SYT-SSX) translocation. PCR products were obtained from 221 tumors (88.5%). There were 135 non-SS tumors, 22 biphasic, and 64 monophasic spindle/round cell SS, of which 10 were cytogenetically confirmed as t(X;18)-positive. SYT-SSX gene fusion transcripts were detected in the SS tumor category only (100% specificity), including 100% of the biphasic SS and 86% of monophasic spindle/round cell SS. Nine tumors originally diagnosed as SS were t(X;18) (SYT-SSX)-negative. Following reassessment, only 3 of these tumors showed clinicopathologic, immunohistochemical, and/or ultrastructural features consistent with that diagnosis, thus raising the overall detection sensitivity to 96%. With regard to the potential adverse effect of the fixatives used, PCR products were obtained in 100%, 91.5%, 90.5%, and 0% of tumors fixed with AFA, buffered formalin, Holland Bouin, and conventional Bouin's fluid, respectively. This study shows that the detection of the SS t(X;18) (SYT-SSX) in paraffin-embedded tissue is feasible with a 100% specificity and an overall 96% sensitivity, provided non-Bouin's fluid fixation is used.
Collapse
MESH Headings
- Adult
- Biomarkers, Tumor
- Chromosomes, Human, Pair 18/genetics
- DNA, Complementary/genetics
- Female
- Fixatives
- Humans
- Male
- Middle Aged
- Neoplasms, Connective and Soft Tissue/genetics
- Neoplasms, Connective and Soft Tissue/pathology
- Oncogene Proteins, Fusion/genetics
- Paraffin Embedding
- Pathology, Clinical
- RNA, Neoplasm/genetics
- Reproducibility of Results
- Reverse Transcriptase Polymerase Chain Reaction
- Sarcoma, Synovial/genetics
- Sarcoma, Synovial/pathology
- Translocation, Genetic
- X Chromosome/genetics
Collapse
Affiliation(s)
- L Guillou
- University Institute of Pathology, Lausanne, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Bühler S, Michels J, Wendt S, Rück A, Brdiczka D, Welte W, Przybylski M. Mass spectrometric mapping of ion channel proteins (porins) and identification of their supramolecular membrane assembly. Proteins 1998; Suppl 2:63-73. [PMID: 9849911 DOI: 10.1002/(sici)1097-0134(1998)33:2+<63::aid-prot8>3.3.co;2-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Mass spectrometric peptide mapping, particularly by matrix-assisted laser desorption-ionization (MALDI-MS), has recently been shown to be an efficient tool for the primary structure characterization of proteins. In combination with in situ proteolytic digestion of proteins separated by one- and two-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), mass spectrometric peptide mapping permits identification of proteins from complex mixtures such as cell lysates. In this study we have investigated several ion channel membrane proteins (porins) and their supramolecular assembly in mitochondrial membranes by peptide mapping in solution and upon digestion in the gel matrix. Porins are integral membrane proteins serving as nonspecific diffusion pores or as specific systems for the transport of substrates through bacterial and mitochondrial membranes. The well-characterized porin from Rhodobacter capsulatus (R.c.-porin) has been found to be a native trimeric complex by the crystal structure and was used as a model system in this study. R.c.-porin was characterized by MALDI-MS peptide mapping in solution, and by direct in situ-gel digestion of the trimer. Furthermore, in this study we demonstrate the direct identification of the noncovalent complex between a mitochondrial porin and the adenine nucleotide translocator from rat liver, by MALDI-MS determination of the specific peptides due to both protein sequences in the SDS-PAGE gel band. The combination of native gel electrophoresis and mass spectrometric peptide mapping of the specific gel bands should be developed as a powerful tool for the molecular identification of protein interactions.
Collapse
Affiliation(s)
- S Bühler
- Faculty of Chemistry, University of Konstanz, Germany
| | | | | | | | | | | | | |
Collapse
|
38
|
Michels J, Wandelt K. Determination of lateral interaction energies in AgAu alloy films on Ru(0001) by Monte Carlo simulations. J Chem Phys 1998. [DOI: 10.1063/1.475824] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
39
|
Affiliation(s)
- C van Weel
- Department of General Practice and Social Medicine, University of Nijmegen, Netherlands
| | | |
Collapse
|
40
|
Abstract
Within a screening program, 91 fungal strains belonging to 32 genera of different ecological and taxonomic groups (wood- and litter-decaying basidiomycetes, saprophytic micromycetes) were tested for their ability to metabolize and mineralize 2,4,6-trinitrotoluene (TNT). All these strains metabolized TNT rapidly by forming monoaminodinitrotoluenes (AmDNT). Micromycetes produced higher amounts of AmDNT than did wood- and litter-decaying basidiomycetes. A significant mineralization of [14C]TNT was only observed for certain wood- and litter-decaying basidiomycetes. The most active strains, Clitocybula dusenii TMb12 and Stropharia rugosa-annulata DSM11372 mineralized 42% and 36% respectively of the initial added [14C]TNT (100 microM corresponding to 4.75 microCi/l) to 14CO2 within 64 days. Micromycetes (deuteromycetes, ascomycetes, zygomycetes) proved to be unable to mineralize [14C]TNT significantly.
Collapse
Affiliation(s)
- K Scheibner
- Friedrich Schiller Universität Jena, Institut für Mikrobiologie, Lehrstuhl Technische Mikrobiologie, Germany.
| | | | | | | | | |
Collapse
|
41
|
Abstract
49 undergraduate men and 45 women took Schill's 1990 Self-defeating Personality Scale and answered questions about their physical health and misbehavior as children and the amount of attention such behavior elicited from their parents. No support was found for the idea that individuals who currently score more self-defeating had been more likely to engage in such behavior or had been able to gain attention thereby. In fact, these people reported getting less rather than more attention from parents when they were physically ill. Results were discussed as consistent with prior findings wherein self-defeating individuals have described their parents as being nonsupportive, inconsistent, and rejecting.
Collapse
Affiliation(s)
- T Schill
- Department of Psychology, Southern Illinois University Carbondale 62901-6502, USA
| | | |
Collapse
|
42
|
Michels J, Gottschalk G. Inhibition of the lignin peroxidase of Phanerochaete chrysosporium by hydroxylamino-dinitrotoluene, an early intermediate in the degradation of 2,4,6-trinitrotoluene. Appl Environ Microbiol 1994; 60:187-94. [PMID: 8117077 PMCID: PMC201288 DOI: 10.1128/aem.60.1.187-194.1994] [Citation(s) in RCA: 89] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
The ability of the white rot fungus Phanerochaete chrysosporium to mineralize 2,4,6-trinitrotoluene (TNT) was studied in the concentration range of 0.36 to 20.36 mg/liter. The initial rate of 14CO2 formation was 30% in 4 days at 0.36 mg of [14C]TNT per liter and decreased to 5% in 4 days at 20.36 mg of [14C]TNT per liter. Such a pronounced inhibition was not observed when a mixture of [14C]2-amino-4,6-dinitrotoluene and [14C]4-amino-2,6-dinitrotoluene was used as a substrate. 2-Hydroxylamino-4,6-dinitrotoluene and its isomer 4-hydroxylamino-2,6-dinitrotoluene were identified as the first detectable degradation products of TNT. Their transient accumulation correlated with the inhibition of TNT degradation and of the veratryl alcohol oxidase activity of lignin peroxidase. With purified lignin peroxidase H8, it could be shown that the two isomers of hydroxylamino-dinitrotoluene were oxidized by lignin peroxidase. The corresponding nitroso-dinitrotoluenes apparently were formed, as indicated by the formation of azoxy-tetranitrotoluenes.
Collapse
Affiliation(s)
- J Michels
- Institut für Mikrobiologie, Georg-August-Universität Göttingen, Federal Republic of Germany
| | | |
Collapse
|
43
|
Michels J, Benoni H, Briskot G, Lex J, Schmickler H, Taraz K, Budzikiewicz H, Korth H, Pulverer G. Isolierung und spektroskopische Charakterisierung des Pyoverdin-Chromophors sowie seines 5-Hydroxy-Analogen [1] / Isolation and Spectroscopic Characterization of the Pyoverdin Chromophore and of Its 5-Hydroxy Analogue [1]. ACTA ACUST UNITED AC 1991. [DOI: 10.1515/znc-1991-11-1211] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract The isolation of the common chromophore of the pyoverdins isolated from iron-deficient cultures of fluorescent Pseudomonas strains and of its 5-hydroxy analogue as well as the spectroscopic characterization of the two compounds is described.
Collapse
Affiliation(s)
- J. Michels
- 1Institut für Organische Chemie der Universität zu Köln , Greinstraße 4. D-5000 Köln 41
| | - H. Benoni
- 1Institut für Organische Chemie der Universität zu Köln , Greinstraße 4. D-5000 Köln 41
| | - G. Briskot
- 1Institut für Organische Chemie der Universität zu Köln , Greinstraße 4. D-5000 Köln 41
| | - J. Lex
- 1Institut für Organische Chemie der Universität zu Köln , Greinstraße 4. D-5000 Köln 41
| | - H. Schmickler
- 1Institut für Organische Chemie der Universität zu Köln , Greinstraße 4. D-5000 Köln 41
| | - K. Taraz
- 1Institut für Organische Chemie der Universität zu Köln , Greinstraße 4. D-5000 Köln 41
| | - H. Budzikiewicz
- 1Institut für Organische Chemie der Universität zu Köln , Greinstraße 4. D-5000 Köln 41
| | - H. Korth
- 2Institut für Medizinische Mikrobiologie und Hygiene, Goldenfelsstraße 21, D-5000 Köln 41
| | - G. Pulverer
- 2Institut für Medizinische Mikrobiologie und Hygiene, Goldenfelsstraße 21, D-5000 Köln 41
| |
Collapse
|
44
|
Michels J, Taraz K. Characterization of pyoverdins and their hydrolytic degradation products by fast atom bombardment and tandem mass spectrometry. ACTA ACUST UNITED AC 1991. [DOI: 10.1002/oms.1210261017] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
45
|
Lang R, Michels J, Becker-Berke R, Lukowski K, Vlaho V, Grundmann R. [Sympathetic activity in terminal renal failure and kidney transplants]. Klin Wochenschr 1984; 62:1025-31. [PMID: 6392724 DOI: 10.1007/bf01711725] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Blood pressure as well as noradrenaline, creatinine and electrolytes in blood and urine were compared in normal controls (n = 25), patients with chronic renal failure (n = 39), patients with continuous ambulatory peritoneal dialysis (CAPD) (n = 28) and haemodialysis patients before and after renal transplantation (n = 63). The average blood pressures of the control group and the CAPD patients were lower than those of the renal failure patients without and with haemodialysis. After renal transplantation elevated blood pressure normalised in 18% within the following 6 months. In all groups of patients with renal failure the mean noradrenaline plasma concentration was increased more than three-fold of normal values: 1,470 pg/ml in patients with chronic renal failure, 1,366 pg/ml in CAPD patients and 1,284 pg/ml in patients with haemodialysis. No correlation was found between these elevated noradrenaline plasma levels and blood pressure. However, there was a significant correlation between noradrenaline excretion and sodium excretion. Compared to the controls, the urine excretion of noradrenaline was significantly lower in patients with chronic renal failure and almost zero in patients with dialysis treatment. Two days after renal transplantation the mean noradrenaline urine excretion increased to 15.7 +/- 1.8 micrograms/day and 4 days after transplantation the noradrenaline plasma concentration decreased to 592 +/- 155 pg/ml. Nine months after renal transplantation the creatinine clearance was 76 ml/min and the mean noradrenaline plasma concentration 438 +/- 153 pg/ml. It is concluded that in chronic renal failure the level of noradrenaline plasma concentration is dependent on renal function.
Collapse
|
46
|
|
47
|
Michels J. The Proboscis and Lancets of the Stable Fly. Sci Am 1877. [DOI: 10.1038/scientificamerican12011877-344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|